In this issue, we share exciting developments in ITP presented at this year's 66th American Society of Hematology (ASH) Annual Meeting and Exposition in San Diego, December 7-10, 2024. First, PDSA staff and members of the Pediatric ITP Consortium of North America (ICON) collaborated on research using data from our ITP Natural History Study Registry. Second, PDSA Medical Advisor, David Kuter, MD, highlights results from the LUNA clinical trial for a new drug on the horizon to treat adults and adolescents with ITP, called rilzabrutinib.

CONTENTS:

• Complementary And Alternative Medicine (CAM) Use Reported Among Individuals with Immune Thrombocytopenia (ITP): Data from The ITP Natural History Study Registry
• Results of LUNA’s Phase 3 Clinical Trial for Rilzabrutinib to Treat ITP

CONTENTS:

• Misdiagnosis of Primary Immune Thrombocytopenia (ITP) in the Community Setting and Its Association with Inherited Platelet Disorders: Reporting New Variants of Inherited Platelet Disorders
• Corticosteroids: Read about this treatment approach, mechanism of action, benefits, and side effects.

CONTENTS:

• What is the Role of T Cells in ITP
• Video: My low platelet count causes my anxiety. Is this normal?

CONTENTS:

• The Role of Genomics in ITP
• HMB in ITP

CONTENTS:

• Childhood ITP: School, Sports, Treatment
• Ask the Experts

CONTENTS:

• When and Why You Should Ask For A Second Opinion
• B-Cell Depletion Therapy

CONTENTS:

• The Spleen In Immune Thrombocytopenia
• Is it Safe to Fly with A Low Platelet Count?

CONTENTS:

• When Should You Worry It’s More Than ITP?
• The Jim Tarantino BCDI Hero Award

CONTENTS:

• Glycosylation and Immune Thrombocytopenia (ITP)
• Platelet Growth Factors

CONTENTS:

• What Individuals with ITP and Their Health Care Providers Should Know When Considering Genetic Testing
• How often should I have my platelets checked?

CONTENTS:

• PCOR: What is it and Why is it Important to Patients with a Rare Disease?
• What Causes ITP?

In this issue of the e-news, we want to share with you the preliminary results of a research study that was presented at the 65th American Society of Hematology (ASH) Annual Meeting and Exposition held in San Diego, California, December 9-12, 2023, and involved PDSA staff and many of our medical advisors, in addition to several of PDSA’s patient members representing the voice of the ITP patient. This work was led by Donald Arnold, MD, one of PDSA’s medical advisors and his research associate Emily Sirotich.

CONTENTS:

• Treatment of Critical Bleeding Events in Patients with Immune Thrombocytopenia: A Systemic Review
• ITP Pathogenesis: Understanding the Immune System Attack on our Platelets